Long-Term Impacts of Intense Pulsed Light Therapy on Ocular Surface Health and Tear Film Dynamics in Patients with Dry Eye Disease: Detailed Analysis and Observations Over a 1-Year Follow-Up Period.
Dry eye disease
Intense pulsed light therapy
Longitudinal study
Meibomian gland dysfunction
Ocular surface health
Tear film stability
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
10
06
2024
accepted:
31
07
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
To evaluate the long-term effects of intense pulsed light (IPL) therapy on patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD). A retrospective case series was performed with 110 participants undergoing IPL therapy. Assessments included the eye fitness test (EFT) to gauge subjective symptoms, along with objective measures using the Tearcheck This study documented significant improvements in subjective and objective symptoms associated with DED and MGD. Subjective symptoms measured by the EFT showed an average increase of 9.74 points (range -10 to 28, standard deviation [SD] ± 7.54), indicating reduced symptoms. Objective measures of tear film stability, represented by NIABUT, increased by an average of 4.04 s (range -15.00 to 14.40, SD ± 4.91). Tear film stability evaluation (TFSE) scores decreased by 229.12 points on average (range -1775 to 528, SD ± 384.94), suggesting enhanced tear film stability. OSIE type 1 showed a reduction in inflammation, with a percentage decrease of 4.98% (range -45 to 5, SD ± 7.33). Additionally, OSIE capture time decreased by 3.25 s on average (range -27 to 22, SD ± 10.35), further indicating an improvement in ocular surface health. IPL therapy was shown to be a promising, noninvasive approach for improving quality of life in patients with DED by effectively managing symptoms and stabilizing tear film. The findings support the use of IPL as a sustainable treatment modality for DED associated with MGD.
Identifiants
pubmed: 39150603
doi: 10.1007/s40123-024-01017-7
pii: 10.1007/s40123-024-01017-7
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15:269–75.
pubmed: 28736334
doi: 10.1016/j.jtos.2017.05.005
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.
pubmed: 28736335
doi: 10.1016/j.jtos.2017.05.008
Garcia-Queiruga J, Pena-Verdeal H, Sabucedo-Villamarin B, Giraldez MJ, Garcia-Resua C, Yebra-Pimentel E. A cross-sectional study of non-modifiable and modifiable risk factors of dry eye disease states. Contact Lens Anterior Eye. 2023;46: 101800.
pubmed: 36572605
doi: 10.1016/j.clae.2022.101800
Vidal-Rohr M, Craig JP, Davies LN, Wolffsohn JS. The epidemiology of dry eye disease in the UK: the Aston dry eye study. Contact Lens Anterior Eye. 2023;46: 101837.
pubmed: 37003925
doi: 10.1016/j.clae.2023.101837
García-Marqués JV, Talens-Estarelles C, García-Lázaro S, Wolffsohn JS, Cerviño A. Systemic, environmental and lifestyle risk factors for dry eye disease in a Mediterranean Caucasian population. Contact Lens Anterior Eye. 2022;45: 101539.
pubmed: 34789408
doi: 10.1016/j.clae.2021.101539
Preoteasa LD, Preoteasa D. Assessment of the prevalence and risk factors for dry eye symptoms among Romanian medical students using the ocular surface disease index – a cross-sectional study. BMC Ophthalmol. 2024;24:12.
pubmed: 38182974
pmcid: 10768241
doi: 10.1186/s12886-023-03260-1
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510.
pubmed: 28736340
doi: 10.1016/j.jtos.2017.05.011
Bonzano C, Borroni D, Lancia A, Bonzano E. Doxycycline: from ocular rosacea to COVID-19 anosmia new insight into the coronavirus outbreak. Front Med. 2020;7:200.
doi: 10.3389/fmed.2020.00200
Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, Golebiowski B, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017;15:284–333.
pubmed: 28736336
doi: 10.1016/j.jtos.2017.04.001
García-Ayuso D, Di Pierdomenico J, Moya-Rodríguez E, Valiente-Soriano FJ, Galindo-Romero C, Sobrado-Calvo P. Assessment of dry eye symptoms among university students during the COVID-19 pandemic. Clin Exp Optom. 2022;105:507–13.
pubmed: 34279190
doi: 10.1080/08164622.2021.1945411
Garcia-Queiruga J, Pena-Verdeal H, Sabucedo-Villamarin B, Giraldez MJ, Garcia-Resua C, Yebra-Pimentel E. Meibomian gland secretion quality association with ocular parameters in University students during COVID- 19 restrictions. Int Ophthalmol. 2023;43:2349–62.
pubmed: 36692700
pmcid: 9873396
doi: 10.1007/s10792-023-02632-2
Cartes C, Segovia C, Salinas-Toro D, Goya C, Alonso MJ, Lopez-Solis R, et al. Dry eye and visual display terminal-related symptoms among University students during the coronavirus disease pandemic. Ophthalmic Epidemiol. 2022;29:245–51.
pubmed: 34251964
doi: 10.1080/09286586.2021.1943457
Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15:511–38.
pubmed: 28736341
doi: 10.1016/j.jtos.2017.05.004
Novack GD, Asbell P, Barabino S, Bergamini MVW, Ciolino JB, Foulks GN, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017;15:629–49.
pubmed: 28736344
pmcid: 8557254
doi: 10.1016/j.jtos.2017.05.009
Willcox MDP, Argüeso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15:366–403.
pubmed: 28736338
pmcid: 6035753
doi: 10.1016/j.jtos.2017.03.006
Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575–628.
pubmed: 28736343
doi: 10.1016/j.jtos.2017.05.006
Tashbayev B, Yazdani M, Arita R, Fineide F, Utheim TP. Intense pulsed light treatment in meibomian gland dysfunction: a concise review. Ocul Surf. 2020;18:583–94.
pubmed: 32629039
doi: 10.1016/j.jtos.2020.06.002
Fineide F, Magnø MS, Khan AZ, Chen X, Vehof J, Utheim TP. Intense pulsed light treatment in meibomian gland dysfunction: Past, present, and future. Acta Ophthalmol. 2023. https://doi.org/10.1111/aos.15759 .
doi: 10.1111/aos.15759
pubmed: 37702308
Ballesteros-Sánchez A, Gargallo-Martínez B, Sánchez-González MC, Sánchez-González JM. Intense pulse light combined with low-level light therapy in dry eye disease: a systematic review. Eye Contact Lens. 2023;49:8–13.
pubmed: 36455215
doi: 10.1097/ICL.0000000000000958
Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Optom. 2018;101:23–33.
pubmed: 28585267
doi: 10.1111/cxo.12541
Giannaccare G, Pellegrini M, Scalzo GC, Borselli M, Ceravolo D, Scorcia V. Low-level light therapy versus intense pulsed light for the treatment of meibomian gland dysfunction: preliminary results from a prospective randomized comparative study. Cornea. 2023;42:141–4.
pubmed: 36582033
doi: 10.1097/ICO.0000000000002997
Benyoussef AA, Arzel F, Cochener B. 3-month post-procedural evaluation of a combined intense pulsed light and photo-biomodulation system in the treatment of meibomian gland dysfunction. J Fr Ophtalmol. 2023;46:873–81.
pubmed: 37068975
doi: 10.1016/j.jfo.2022.12.004
Song X, Chen Z, Li J, Wu S, Liang L. Therapeutic efficacy and safety of intense pulsed light for meibomian gland dysfunction in patients with chronic ocular graft-versus-host disease. Ocul Immunol Inflamm. 2023; https://doi.org/10.1080/09273948.2023.2266763 .
Narang P, Donthineni PR, D’Souza S, Basu S. Evaporative dry eye disease due to meibomian gland dysfunction: preferred practice pattern guidelines for diagnosis and treatment. Indian J Ophthalmol. 2023;71:1348–56.
pubmed: 37026266
pmcid: 10276722
doi: 10.4103/IJO.IJO_2841_22
Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12:1397–418.
pubmed: 36856980
pmcid: 10164226
doi: 10.1007/s40123-023-00669-1
Zeng H, Gong L. A review of applications and intracellular mechanisms of intense pulsed light in eyelid inflammatory diseases. Photobiomodul Photomed Laser Surg. 2023;41:104–19.
pubmed: 36927050
Qin G, Chen J, Li L, Zhang Q, Xu L, Yu S, et al. Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: a meta analysis and systematic review. Indian J Ophthalmol. 2023;71:1316–25.
pubmed: 37026263
pmcid: 10276661
doi: 10.4103/IJO.IJO_2987_22
Demolin L, Es-Safi M, Soyfoo MS, Motulsky E. Intense pulsed light therapy in the treatment of dry eye diseases: a systematic review and meta-analysis. J Clin Med. 2023;12:3039.
pubmed: 37109374
pmcid: 10145895
doi: 10.3390/jcm12083039
Pratomo TG, Zaifar A, Wibowo NP, Suryono AN, Aziza Y. Current application of intense pulsed light for the management of dry eye disease: A systematic review and meta-analysis. Indian J Ophthalmol. 2024;72:S183–90.
pubmed: 38146980
doi: 10.4103/IJO.IJO_671_23
Liu C, Zhou Q, Gao ZQ. Efficacy of intense pulsed light and meibomian gland expression treatments in meibomian gland dysfunction: a meta-analysis of randomized controlled trials. Med (United States). 2022;101: e32292.
Lei Y, Peng J, Liu J, Zhong J. Intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD)–related dry eye disease (DED): a systematic review and meta-analysis. Lasers Med Sci. 2023;38:1.
doi: 10.1007/s10103-022-03690-1
Miao S, Yan R, Jia Y, Pan Z. Effect of intense pulsed light therapy in dry eye disease caused by meibomian gland dysfunction: a systematic review and meta-analysis. Eye Contact Lens. 2022;48:424–9.
pubmed: 36044829
doi: 10.1097/ICL.0000000000000934
Ribeiro BB, Marta A, Ramalhão JP, Marques JH, Barbosa I. Pulsed light therapy in the management of dry eye disease: current perspectives. Clin Ophthalmol. 2022;16:3883–93.
doi: 10.2147/OPTH.S349596
Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Investig Ophthalmol Vis Sci. 2011;52:1922–9.
doi: 10.1167/iovs.10-6997a
Benitez-del-Castillo JM, López-Pérez MD, Cano-Ortiz A, Peris-Martinez C, Pinar-Sueiro S, Gessa-Sorroche M, et al. Efficacy and safety of intense pulsed light of upper and lower eyelids in Meibomian gland dysfunction: A prospective multicentric study. Eur J Ophthalmol. 2023. https://doi.org/10.1177/11206721231199121 .
doi: 10.1177/11206721231199121
pubmed: 37844600
Qin G, Chen J, Li L, Xia Y, Zhang Q, Wu Y, et al. Managing severe evaporative dry eye with intense pulsed light therapy. Ophthalmol Ther. 2023;12:1059–71.
pubmed: 36693992
pmcid: 10011255
doi: 10.1007/s40123-023-00649-5
Gouws P, Barabas S, Gouws A. Efficacy of portable 445 nm laser versus intense pulsed light treatment for dry eye: a Prospective randomized pilot study. Photobiomodul Photomed Laser Surg. 2023;41:120–4.
pubmed: 36927052
Ballesteros-Sánchez A, Sánchez-González JM, Gutiérrez-Ortega R, Gargallo-Martínez B. Diamond bur microblepharoexfoliation combined with intense pulse light and meibomian gland expression for evaporative dry eye: a short-term controlled clinical trial. Ophthalmol Ther. 2024. https://doi.org/10.1007/s40123-024-00919-w .
doi: 10.1007/s40123-024-00919-w
pubmed: 38467993
pmcid: 11039584
Yin Y, Gong L, Lu Y. The approach of intense pulsed light treatment in patients with different severities of meibomian gland dysfunction. Curr Eye Res. 2023;48:231–7.
pubmed: 36408882
doi: 10.1080/02713683.2022.2147955
Chung HS, Han YE, Lee H, Kim JY, Tchah H. Intense pulsed light treatment of the upper and lower eyelids in patients with moderate-to-severe meibomian gland dysfunction. Int Ophthalmol. 2023;43:73–82.
pubmed: 35794405
doi: 10.1007/s10792-022-02389-0
Jiang X, Yuan H, Zhang M, Lv H, Chou Y, Yang J, et al. The efficacy and safety of new-generation intense pulsed light in the treatment of meibomian gland dysfunction-related dry eye: a multicenter, randomized, patients-blind, parallel-control. Non-Inferior Clin Trial Ophthalmol Ther. 2022;11:1895–912.
Trone MC, Garcin T, Ollier E, Thuret G, Gain P. A retrospective study of the efficacy of intense pulsed light delivered by the Lacrystim
pubmed: 35933379
pmcid: 9356507
doi: 10.1186/s12886-022-02531-7
Min JS, Yoon SH, Kim KY, Jun I, Kim EK, Kim TI, et al. Treatment effect and pain during treatment with intense pulsed-light therapy according to the light guide in patients with meibomian gland dysfunction. Cornea. 2022;41:177–82.
pubmed: 34469338
doi: 10.1097/ICO.0000000000002859
Fukuoka S, Arita R. Comparison of intense pulsed light therapy on patients with meibomian gland dysfunction using AQUA CEL and M22 devices. J Clin Med. 2022;11:4265.
pubmed: 35893356
pmcid: 9332253
doi: 10.3390/jcm11154265
Zarei-Ghanavati S, Hassanzadeh S, Azimi Khorasani A, Ehsaei A, Bakhtiari E. Efficacy of five-flash intense pulsed light therapy technique in patients with meibomian gland dysfunction. Clin Exp Optom. 2022;105:687–93.
pubmed: 34538227
doi: 10.1080/08164622.2021.1976595